FindMyKOL

Shyam Tanguturi, MD

Enriched profile

Vice Chair of Network Strategy and Business Development for MGB Radiation Oncology · Mass General Brigham

ORCID↗NPI↗
✓ Itemized profile
Region🇺🇸 Boston, MA · Northeast · United StatesSpecialtyRadiation OncologyFocusGlioma Diagnosis and Treatment+4
Active KOLFindMyKOL type: RegionalLatest publication2026Online presenceverified 2026Payments2022–2025NIH fundingNone on fileWhy? →

Shyam Tanguturi is Vice Chair of Network Strategy and Business Development for MGB Radiation Oncology at Mass General Brigham. OpenAlex indexes 101 publications with 1,691 citations (h-index 20); ClinicalTrials.gov lists 1 registered study with this person as an investigator.

Data verified 5 Nov 2026

Overview

Updated 5 Nov 2026

Shyam Tanguturi, M.D., is Vice Chair of Network Strategy and Business Development for MGB Radiation Oncology at Mass General Brigham. The public record shows 101 publications with 1,691 citations (h-index 20), centered on Glioma Diagnosis and Treatment, Brain Metastases and Treatment, Management of metastatic bone disease. It also documents an investigator role on 1 registered clinical trials, industry payments reported by 6 companies.

  • Most recent indexed publication: 2026 · JNCI cancer spectrum
  • Top research focus: Glioma Diagnosis and Treatment
  • 1 registered trials on ClinicalTrials.gov
  • Open Payments reporting from 6 companies

Generated from the cited public record · current as of 5 Nov 2026. Every fact links its source below.

Indications focus

from trials led + research topics
Neuro-Oncology / Glioma1 trialMelanomaProstate CancerLeukemia (AML/ALL/CML/CLL)Kidney Cancer / RCCSarcomaHepatobiliary CancerAcromegalyLymphomaOvarian / Gynecologic CancerHead & Neck CancerTuberculosisMultiple MyelomaColorectal CancerLung Cancer (NSCLC/SCLC)Breast Cancer

Research focus

OpenAlex concept fingerprint
Glioma Diagnosis and TreatmentBrain Metastases and TreatmentManagement of metastatic bone diseaseAdvanced Radiotherapy TechniquesPARP inhibition in cancer therapy

Works with

trial sponsors and companies reporting payments
Viewray Technologies IncClinical trials—Industry payments4IBA Proton Therapy, Inc.Clinical trials—Industry payments3Mevion_Medical_Systems_IncClinical trials—Industry payments3Servier Pharmaceuticals LLCClinical trials—Industry payments2Dana-Farber Cancer InstituteClinical trials1Industry payments—MIM Software Inc.Clinical trials—Industry payments1Monteris Medical CorporationClinical trials—Industry payments1

Scholarship

indexed output and impact (OpenAlex)
View publications ↓
101publications

Publications indexed by OpenAlex, matched via ORCID. 10 in PubMed. Counts exclude supporting files.

1,691citations

Citations across these publications.

20h-index

H-index from these publications. i10-index 30.

Clinical & industry

trials, payments and federal funding
1clinical trials

Investigator role on registered studies.

View trials ↓
6companies · 2022–2025

Companies reporting payments to CMS. Facts, not judgments.

View payments ↓
0NIH grants

Federally funded research awards.

Contact

The practice address and phone this provider lists in the federal NPPES (CMS) registry.

Practice address

Telephone

Practice address and telephone from the federal NPPES registry.

Sign in to view contact details →

Clinical trials

Updated 5 Nov 2026

Listed as an investigator on 1 registered study on ClinicalTrials.gov. The most recent:

Industry payments

Updated 5 Nov 2026

6 companies reported payments to CMS in program years 2022–2025. These are public disclosures, not judgments. The latest:

All 8 payment records: search, sort and filter.Explore →
View the CMS Open Payments record ↗

Medicare prescribing footprint (2024)

The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.

  • Sensory organs

    52%
    Corticosteroid52%
    Dexamethasone100%
    Part D<11 patients

  • Nervous system

    48%
    N-methyl-D-aspartate Receptor Antagonist48%
    Memantine Hcl100%
    Part D<11 patients
Where care is delivered (Part B)92.1% facility · 7.9% office

Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.

NIH funding

We didn't find any NIH-funded research awards for this person in NIH RePORTER. Why? →

Congress activity

Updated 5 Nov 2026

39 congress contributions (2013–2026) across ASCO, ASTRO, SNO per OpenAlex. The most recent:

All 39 congress records: search, sort and filter.Explore →

Published abstracts are attributed via the same ORCID-disambiguated authorship as publications, so each is DOI-verified. Podium roles (invited talks, session chairs) and oral/poster type are added as program data is confirmed.

Publications

Updated 5 Nov 2026

Their five most recent publications, matched to their ORCID record and linked to PubMed.

All 10 publications: search, sort and filter.Explore →

Most-cited works

by citation count (OpenAlex)
All 101 cited works: search, sort and filter.Explore →

Network

Updated 5 Nov 2026

The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.

Patrick Yung Wen46Ayal Aaron Aizer42Rifaquat M. Rahman39Daphne Adele Haas-Kogan39Brian Michael Alexander32Daniel N. Cagney27Paul J. Catalano26Eudocia Q. Lee24David A. Reardon24Keith Lloyd Ligon23Nayan Lamba20Lakshmi Nayak19Wenya Linda Bi19Ugonma Nnenna Chukwueke16Jose Ricardo McFaline-Figueroa15Lorenzo Trippa14Omar M. Arnaout13Kee‐Young Shin11Ennio Antonio Chiocca11Manmeet Singh Ahluwalia11Rameen Beroukhim11Raymond H. Mak11Jaroslaw T. Hepel11Diana D. Shi9Lisa M. Doherty8Mary Roberta Welch8Evanthia Galanis8Geoffrey G. Fell8David Schiff8Isabel Arrillaga‐Romany8Gilbert Youssef8Howard Colman8David M. Meredith8Christine Lu‐Emerson8Tracy T. Batchelor8Burt Nabors8Itai Max Pashtan8Jan Drappatz8Mai Anh Huynh8Mikael L. Rinne7

Online presence

Updated 5 Nov 2026

This person's own public accounts first, then places where others mention them. Two different things, listed separately.

Owned accounts

public accounts run by this person
  • Doximity

    doximity.com/pub/shyam-tanguturi-md

    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →doximity.com ↗

We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.

Background & recognition

Updated 5 Nov 2026

Credentials, appointments and honors, newest first, each linked to the public source it came from.

Education

degrees and training on record

Secondary affiliations

appointments beyond the home institution
  • Dana-Farber Cancer Institute

    Senior Physician

    verifiedCorroborated by FindMyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →dana-farber.org ↗
  • Harvard Medical School

    Assistant Professor of Radiation Oncology (rank listed inconsistently across sources)

    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →dana-farber.org ↗

Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.

Similar KOLs

Other experts from the same institution or the same specialty.